Monitoring the safety of targeted drugs for pulmonary hypertension using a computerized system

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to recruit at least 700 patients diagnosed with various forms of pulmonary hypertension and follow them up every six months using a computerized follow-up system. The primary focus is to monitor adverse drug events and all-cause mortality among participants receiving targeted therapies. By systematically collecting and analyzing data, the study seeks to enhance understanding of the safety profiles of these medications in a real-world setting. The study will include patients aged from 3 months to 85 years who meet specific diagnostic criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age from 3 months to 85 years, no sex preference;
* Right heart catheter meet the following conditions simultaneously: mPAP≥25mmHg, and PVR \> 3 Wood units(in children PVRi \> 3 WU x m2), and PAWP≤15 mmHg at rest;
* Patients diagnosed with group 1,2,4,5 PH according to the WHO classification, detailed description is as follows: Pulmonary arterial hypertension, Lung disease / chronic hypoxia associated pulmonary hypertension, Pulmonary hypertension associated with pulmonary artery stenosis / obstruction and Pulmonary hypertension caused by other multiple factors
* Take at least one pulmonary hypertension targeted drug or calcium antagonist;
* Signed written informed consent.

Exclusion Criteria:

* Patients diagnosed with pulmonary hypertension related to left heart disease;

Where it's running

• Fuwai Hospital, Chinese Academy of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Lu Hua, M.D — Chinese Academy of Medical Sciences, Fuwai Hospital
• Study coordinator: Tingting Guo, M.D
• Email: 18610094559@163.com
• Phone: +86 18610094559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD

  This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.

  Recruiting at 2 sites Early Phase 1 Valley Health System · Paramus, New Jersey and 1 other locations · NCT07837830

• Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension

  This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.

  Recruiting Hospital de Clinicas de Porto Alegre · Porto Alegre · NCT07822997

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Pulmonary Artery Denervation for Pulmonary Hypertension After M-TEER

  This study tests whether PADN can help people with pulmonary hypertension after M-TEER compared with standard medical therapy.

  Recruiting Early Phase 1 Xiamen Cardiovascular Hospital, Xiamen University · Xiamen, Fujian · NCT07662655

• Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

  This study tests how to identify people with pulmonary hypertension who are at risk of a sudden, life-threatening crisis.

  Recruiting at 4 sites Peking Union Medical College Hospital · Guangzhou, Guangdong and 3 other locations · NCT07653958

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.